Vitrolife receives FDA approval for RapitVit Blast and RapidWarm Blast vitrification products

“The majority of clinics in the USA that vitrify embryos do so at the blastocyst stage. This approval means that Vitrolife gains both access to yet another non-processed market and opportunities for additional sales to current customers”

Vitrolife (STO:VITR) has received approval from the U.S. Food and Drug Administration, FDA, the equivalent of the Swedish Medical Products Agency, for the products RapitVit™ Blast and RapidWarm™ Blast. So-called 510(k) clearance has been obtained for these products, which are used for so-called vitrification, the rapid freezing and thawing of blastocysts (embryos days 5-7 after fertilization). Vitrolife has since before approved products for vitrification of embryos in an earlier stage of the fertilization (embryos day 2-3 after fertilization).

Products for vitrification involve considerable technological progress and open up new opportunities within in vitro fertlization (IVF) treatment. Vitrification involves very rapid freezing, to prevent the formation of ice crystals that otherwise can destroy the cells.

In IVF treatment, the woman has been stimulated with hormones and has more oocytes than normal. The oocytes that are fertilized but not put back in the woman can then be kept in cold storage. Clinical studies have shown that using the vitrification method considerably increases survival after cold storage compared with the previously used method. The chance of the woman getting pregnant again thereby also increases, without her having to undergo new hormone treatment and the removal of more oocytes.

RapitVit™ Blast and RapidWarm™ Blast have been previously approved in Europe and Canada.

The products will be launched on the American market as from the end of December 2010.

"The majority of clinics in the USA that vitrify embryos do so at the blastocyst stage. This approval means that Vitrolife gains both access to yet another non-processed market and opportunities for additional sales to current customers," says Nils Sellbom, Director of Marketing and Sales at Vitrolife.

December 21, 2010

Gothenburg

Magnus Nilsson

CEO

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ultra-processed foods dominate children's diets from toddlerhood to middle childhood